Sanjivani Paranteral (SANJIVIN) | Stock Overview & Key Data
Sanjivani Paranteral Performance Comparison
Stock Range
Today's Range
Low: ₹211.90
High: ₹225.00
on October 7, 2025
52 Week Range
Low: ₹203.10
High: ₹396.95
on August 22, 2025
on December 31, 2024
All-Time High: ₹396.95 on December 30, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR2.8B
EPS
6.60
P/E Ratio (TTM)
34.50
Forward P/E
N/A
P/B Ratio
7.12
PEG Ratio
-50.71
Div. Yield
N/A
ROE
20.31%
Beta
-0.884
Debt to Equity
20.42
Financial Highlights
Profitability
Gross Margin
37.88%
Operating Margin
13.88%
Profit Margin
11.34%
Returns and Earnings
Return on Assets (TTM)
10.35%
Return on Equity (TTM)
20.31%
EBITDA
INR116.5M
Net Income (TTM)
INR81.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR60.22
Quarterly Revenue Growth (YoY)
8.90%
Quarterly Earnings Growth (YoY)
1.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sanjivani Paranteral SANJIVIN | 2.83B Small-cap | -2.46% | -9.50% | 2.13% | -3.83% | -41.73% | -25.39% | 348.49% | 2,289.37% |
| Sun Pharmaceutical SUNPHARMA | 4.01T Large-cap | 4.12% | 4.66% | -1.50% | -0.70% | -12.45% | -13.00% | 69.49% | 239.84% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 2.26% | -3.33% | -15.42% | 10.79% | -4.06% | -5.14% | 63.08% | 80.80% |
| Innova Captab INNOVACAP | 48.64B Small-cap | 0.46% | -4.62% | -2.11% | -0.23% | -24.99% | 16.46% | 53.72% | 53.72% |
| Suven Life Sciences SUVEN | 47.99B Small-cap | 3.79% | -10.27% | -21.82% | 76.25% | 63.70% | 49.21% | 215.69% | 329.98% |
| Gujarat Themis GUJTHEM | 46.19B Small-cap | 5.81% | 11.73% | 24.24% | 72.58% | 76.09% | 95.83% | 95.83% | 95.83% |
Ownership & Short Interest
Insider Ownership
58.15%
Institutional Ownership
1.07%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
4K
Average 90-Day Volume
10K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SANJIVIN's 52-week high and low?
- In the last 52 weeks, Sanjivani Paranteral reached a high of ₹396.95 (on December 31, 2024) and a low of ₹203.10 (on August 22, 2025).
- What is the market cap and P/E ratio for SANJIVIN?
- Curious about Sanjivani Paranteral's size and valuation? Its market capitalization stands at 2.83B. When it comes to valuation, the P/E ratio (trailing twelve months) is 34.50, and the forward P/E (looking ahead) is N/A.
- Does SANJIVIN pay dividends? If so, what's the yield?
- As for dividends, Sanjivani Paranteral isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sanjivani Paranteral's main competitors or similar companies to consider before investing?
When looking at Sanjivani Paranteral, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA4.01T Healthcare Drug Manufacturers - Specialty & Generic -13.00% 69.49% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic -5.14% 63.08% Innova Captab
INNOVACAP48.64B Healthcare Drug Manufacturers - Specialty & Generic 16.46% 53.72% Suven Life Sciences
SUVEN47.99B Healthcare Drug Manufacturers - Specialty & Generic 49.21% 215.69% Gujarat Themis
GUJTHEM46.19B Healthcare Drug Manufacturers - Specialty & Generic 95.83% 95.83% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sanjivani Paranteral Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Sanjivani Paranteral's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 20.31%, the Debt to Equity ratio from the most recent quarter is 20.42, and its Gross Profit Margin stands at 37.88%.
- What is the recent revenue and earnings growth for SANJIVIN?
- Looking at Sanjivani Paranteral's growth, its revenue over the trailing twelve months (TTM) was INR716M. Compared to the same quarter last year (YoY), quarterly revenue grew by 8.90%, and quarterly earnings saw a YoY growth of 1.00%.
- How much of SANJIVIN stock is held by insiders and institutions?
- Wondering who owns Sanjivani Paranteral stock? Company insiders (like executives and directors) hold about 58.15% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 1.07%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.